Yfmt (Not yet branded)
Other Medications
Description
Yfmt is a microbiome-based therapeutic agent designed to enhance immune checkpoint inhibitor efficacy in patients with microsatellite stable (MSS) colorectal cancer. This treatment consists of specifically selected healthy gut bacterial strains that aim to overcome resistance to immunotherapy in MSS tumors, which typically show poor response to immune checkpoint blockade. Yfmt is administered in combination with immune checkpoint inhibitors to potentially convert immunologically "cold" MSS colorectal tumors into "hot" tumors that are more susceptible to immune-mediated destruction.
Mechanism of Action
Yfmt works by introducing beneficial bacterial strains into the gut microbiome that can modulate the tumor immune microenvironment and enhance T-cell infiltration into MSS colorectal tumors. The specific bacterial strains are selected for their ability to produce metabolites and immune-stimulating factors that promote antigen presentation, increase interferon signaling, and reduce immunosuppressive factors within the tumor microenvironment. This microbiome modulation aims to sensitize otherwise immune-resistant MSS colorectal cancers to checkpoint inhibitor therapy.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.